AMDL Announces Sales of $5.8 Million for Third Quarter 2007 Results
November 19 2007 - 5:08PM
PR Newswire (US)
TUSTIN, Calif., Nov. 19 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (JPI), an international
biopharma company, announced today that it generated sales of
approximately $5.8 million for the third quarter of 2007 compared
to $2.3 million for the second quarter of 2007. Net income for the
third quarter was approximately $630,000 (unaudited) or $0.05 cents
per share, which includes approximately $250,000 of gain on foreign
currency translation. The results for the three months ended
September 30, 2007 reflect the first quarter of profitable
operations since the Company's inception. Mr. Gary Dreher, CEO of
AMDL, noted that, "AMDL's introduction of new products and
increased distribution channels caused the upturn in revenues
demonstrates that JPI should continue to provide earnings in the
future. We anticipate that our Chinese subsidiaries will continue
to experience strong sales and gross profit growth that will
greatly improve AMDL's combined operating results." About AMDL:
More information about AMDL and its products can be obtained at
http://www.amdl.com/. AMDL, together with Jade, engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products. About Jade: Jade has access
to the fastest growing pharmaceutical and consumer market in the
world: China. AMDL, through its Jade subsidiaries, currently holds
licenses for 133 products that are manufactured as large volume
injection fluids, tablets and other related products. It currently
manufactures over 20 key generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. Forward-Looking Statements: This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 Voice Mail: 714.505.4460 For Immediate Release
DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, AMDL Investor
Relations, +1-949-707-5365, +1-714-505-4460, for AMDL, Inc. Web
site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024